Clinicopathological parameters | Total mast cells [median (IQR)/1 mm2] | P | Peritumoural mast cells [median (IQR)/1 mm2] | P | Intratumoural mast cells [median (IQR)/1 mm2] | P |
---|---|---|---|---|---|---|
Histological type (n = 134) | ||||||
Carcinoma simple (n = 24) | 225 (132) | NS | 180 (181) | NS | 60 (64) | NS |
Carcinoma solid (n = 19) | 168 (160) | 144 (124) | 50 (66) | |||
Comedocarcinoma (n = 9) | 138 (234) | 120 (165) | 18 (71) | |||
Carcinoma arising in a complex/mixed tumour (n = 3) | 1221 | 981 | 291 | |||
Carcinoma complex (n = 30) | 138 (108) | 113 (100) | 31.5 (43) | |||
Carcinoma mixed (n = 32) | 152 (187) | 127 (165) | 18.5 (60) | |||
Intraductal papillary carcinoma (n = 13) | 106 (189) | 100 (105) | 22 (47) | |||
Adenosquamous carcinoma (n = 4) | 195 (108) | 147 (85) | 48 (58) | |||
Histological grade (n = 134) | ||||||
Grade I (n = 73) | 150 (153) | NS | 114 (122)a | 0.041 | 29 (62) | NS |
Grade II (n = 34) | 173 (194) | 164 (170)a | 50 (53) | |||
Grade III (n = 27) | 168 (170) | 140 (116) | 48 (75) | |||
Tumour necrosis (n = 134) | ||||||
Absent (n = 73) | 164 (161) | NS | 136 (119) | NS | 35 (65) | NS |
Present (n = 61) | 168 (167) | 136 (119) | 48 (59) | |||
Tumour-infiltrating lymphocytes (n = 112) lymphocytes (n = 114) | ||||||
Low (n = 55) | 140 (142) | NS | 100 (114) | NS | 30 (49)a | 0.41 |
Moderate (n = 38) | 172 (142) | 137 (128) | 28.5 (42) | |||
High (n = 19) | 194 (118) | 153 (106) | 64 (74)a | |||
Proliferation index (n = 134) | ||||||
≤ 11% (n = 66) | 144 (156) | NS | 118.5 (138) | NS | 26 (63) | NS |
> 11% (n = 67) | 170 (134) | 142 (84) | 50 (61) | |||
Tumour size (n = 45) | ||||||
T1 < 3 cm (n = 11) | 90 (153) | NS | 76 (155) | NS | 18 (46) | 0.02 |
T2 3–5 cm (n = 10) | 152 (156) | 127.5 (142) | 15 (40)a | |||
T3 > 5 cm (n = 24) | 174 (158) | 118 (120) | 50 (66)a | |||
Lymph node metastasis (n = 45) | ||||||
No (n = 35) | 111 (155) | NS | 97.5 (144) | NS | 14 (19) | 0.024 |
Yes (n = 10) | 166 (127) | 118 (118) | 48 (55) |